The Pharma Data

DECEMBER 2, 2020

Additionally, HZI is looking to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients. aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. to establish a new joint venture company, Nanjing AuroRNA Biotech Co., in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. Reagents that can augment and enhance ADCC are of interest in addition to the antibodies themselves. These models have greatly contributed to the clinical development of several tumour immunotherapies.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. Talking Medicines – Scotland’s Talking Medicines will join Tech Nation’s Applied AI 2.0

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52